Your browser is no longer supported. Please, upgrade your browser.
Settings
SAVA [NASD]
Cassava Sciences, Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own1.90% Shs Outstand39.95M Perf Week-3.50%
Market Cap2.07B Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float37.46M Perf Month13.06%
Income-12.70M PEG- EPS next Q-0.16 Inst Own27.50% Short Float23.42% Perf Quarter-39.59%
Sales- P/S- EPS this Y8.80% Inst Trans0.11% Short Ratio1.05 Perf Half Y46.19%
Book/sh6.92 P/B7.18 EPS next Y25.40% ROA-7.40% Target Price- Perf Year356.29%
Cash/sh6.68 P/C7.44 EPS next 5Y- ROE-7.50% 52W Range6.70 - 146.16 Perf YTD628.59%
Dividend- P/FCF- EPS past 5Y35.40% ROI- 52W High-66.00% Beta0.73
Dividend %- Quick Ratio60.30 Sales past 5Y- Gross Margin- 52W Low641.64% ATR5.43
Employees11 Current Ratio60.30 Sales Q/Q- Oper. Margin- RSI (14)40.68 Volatility8.84% 11.46%
OptionableYes Debt/Eq0.00 EPS Q/Q-179.80% Profit Margin- Rel Volume0.45 Prev Close53.37
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume8.32M Price49.69
Recom2.00 SMA20-11.48% SMA50-29.02% SMA200-14.84% Volume3,708,834 Change-6.90%
Jul-15-21Downgrade Cantor Fitzgerald Overweight → Neutral $100
Jul-07-21Reiterated Maxim Group Buy $80 → $190
Apr-27-21Initiated B. Riley Securities Buy $78
Feb-16-21Reiterated H.C. Wainwright Buy $20 → $66
Oct-23-20Initiated Cantor Fitzgerald Overweight $24
Sep-23-20Upgrade H.C. Wainwright Neutral → Buy $20
May-18-20Downgrade H.C. Wainwright Buy → Neutral
May-15-20Downgrade Maxim Group Buy → Hold
Jan-10-20Reiterated Maxim Group Buy $3 → $12
Oct-16-21 01:00AM  
Oct-15-21 10:50PM  
09:06PM  
08:49PM  
05:30PM  
04:59PM  
03:15PM  
02:50PM  
09:23AM  
08:30AM  
05:45AM  
Oct-14-21 10:30PM  
07:40PM  
06:48PM  
05:15PM  
04:08PM  
01:49PM  
11:15AM  
10:25AM  
10:00AM  
08:45AM  
06:02AM  
Oct-13-21 10:28PM  
10:00PM  
08:31PM  
06:40PM  
05:30PM  
04:31PM  
04:19PM  
04:00PM  
04:00PM  
02:32PM  
12:30PM  
12:05PM  
12:00PM  
10:23AM  
08:45AM  
05:20AM  
Oct-12-21 10:43PM  
08:10PM  
08:01PM  
06:28PM  
05:15PM  
04:30PM  
04:30PM  
03:55PM  
03:30PM  
01:30PM  
12:20PM  
11:38AM  
11:00AM  
09:46AM  
09:10AM  
09:00AM  
05:32AM  
01:08AM  
Oct-11-21 10:25PM  
06:18PM  
06:11PM  
05:50PM  
04:20PM  
04:15PM  
03:37PM  
03:15PM  
01:21PM  
12:30PM  
11:00AM  
11:00AM  
09:15AM  
08:45AM  
05:32AM  
Oct-10-21 05:40PM  
08:29AM  
08:29AM  
Oct-09-21 09:06PM  
12:03PM  
10:43AM  
08:55AM  
08:03AM  
Oct-08-21 10:50PM  
07:40PM  
04:35PM  
03:05PM  
01:05PM  
11:31AM  
11:05AM  
09:07AM  
08:15AM  
Oct-07-21 10:50PM  
10:00PM  
07:32PM  
07:20PM  
06:51PM  
06:41PM  
04:32PM  
01:47PM  
01:39PM  
12:10PM  
10:49AM  
10:30AM  
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GUSSIN ROBERT ZDirectorSep 15Option Exercise27.372,80176,6636,710Sep 21 04:01 PM
BARBIER REMIPresident and CEOJul 20Option Exercise20.232,80156,664326,652Jul 20 05:21 PM
BARBIER REMIPresident and CEOMay 27Option Exercise53.5556,0303,000,4061,134,885May 28 04:01 PM
ROBERTSON SANFORDDirectorMar 30Option Exercise40.897,472305,521920,095Mar 31 09:14 PM
FRIEDMANN NADAVChief Medical OfficerMar 17Option Exercise53.5528,0151,500,20392,428Mar 18 04:06 PM
O DONNELL MICHAEL JDirectorMar 16Option Exercise49.004,669228,7819,257Mar 18 03:59 PM